Tennessee Retina Physicians Present at ASRS 43rd Annual Scientific Meeting
Tennessee Retina Physicians Present at ASRS 2025 Annual Meeting
At Tennessee Retina, we are proud to be a part of shaping the future of retinal care. Recently, four of our physicians gathered alongside retina specialists from around the world in Long Beach, California, for The American Society of Retina Specialists (ASRS), 43rd Annual Scientific Meeting. This highly respected event showcases the latest in retina research, treatment strategies, and emerging technology.
We’re proud to share that three of our physicians presented research and clinical findings at this year’s meeting:
Dr. Eric W. Schneider
Topic: Aflibercept 8mg in Diabetic Macular Edema: 156-Week Results from the PHOTON Extension Study
Dr. Schneider presented long-term data from the PHOTON Extension Study, a major trial evaluating the use of aflibercept 8mg in treating diabetic macular edema—a leading cause of vision loss in patients with diabetes. These extended results offer valuable insight into how sustained treatment may benefit patients over time.
Dr. David A. Reichstein
Topic: Independent Validation of a 16-Protein Test to Assess Malignant Potential of Small Uveal Melanocyte Tumors
Dr. Reichstein’s work focuses on improving early diagnosis and risk assessment for uveal melanocyte tumors. His presentation shared findings that could help physicians more accurately identify which small tumors are likely to become malignant, potentially improving outcomes through earlier, more targeted intervention.
Dr. Hesham K. Gabr
Topic: Surgical Outcomes for Proliferative Sickle Cell Retinopathy
Dr. Gabr discussed surgical strategies and outcomes for patients with proliferative sickle cell retinopathy, a serious and often vision-threatening complication of sickle cell disease. His research aims to enhance treatment options and improve long-term vision preservation in affected patients.
Dr. Carl C. Awh
Topic: Efficacy and Safety of Biosimilar Aflibercept-ayyh in Clinical Use by a Consortium of Retina Practices
Dr. Awh is presenting real-world data on the safety and effectiveness of biosimilar aflibercept-ayyh, an emerging treatment alternative in retina care. His research, conducted through a consortium of retina practices, offers valuable insight into how biosimilars may expand access while maintaining high standards of care for patients requiring anti-VEGF therapy.
Advancing Retina Care Through Innovation and Collaboration
The ASRS Annual Meeting is a forum where specialists share the latest evidence-based practices, breakthrough technologies, and treatment innovations.
Our physicians’ involvement is a reflection of Tennessee Retina’s ongoing commitment to academic excellence, clinical leadership, and—most importantly—our patients. By contributing to discussions at the national and international level, we ensure our care remains informed by the latest science and shaped by a community of forward-thinking retina experts.
We are incredibly proud of Drs. Schneider, Reichstein, Gabr, and Awh for representing Tennessee Retina at ASRS 2025, and we look forward to bringing their knowledge and experience back to the patients we serve every day.
